



UK Impact Report

»» Year ending 31 December 2025

Sofia and the
rest of the DKMS
Sahara trekkers team



Our Vision

To delete blood cancer.



Our Mission

To give as many blood cancer patients as possible a second chance at life.



Our Purpose

To raise awareness of blood cancer and blood disorders, register and retain potential stem cell donors to provide a second chance at life, raise funds to match donor registration costs, provide access to transplantation for more blood cancer patients, and improve blood cancer therapies by our own research.

Contents

Managing Directors' introduction	Page 03
01 Leo's army	Page 05
02 Singing along and signing up	Page 07
03 A gala for hope and remembrance	Page 09
04 Giving back during Ramadan	Page 11
05 Trekking for Amelie	Page 13
06 Listen to your Aunties!	Page 15
07 Lucy and Harvey: a transatlantic story	Page 17
Statement of financial activities	Page 19
Ways you can support us	Page 43

Managing Directors' Introduction

Dear friends and supporters,

Welcome to the DKMS UK 2025 Impact Report. I'm grateful for the opportunity to reflect on a year of achievements, as we continue in our mission to give patients with blood cancer and blood disorders a second chance at life.

2025 was of great significance to me personally, as it marked my first full year as Managing Director of this wonderful charity – one I was proud to support as a volunteer long before stepping into this role.

And what a twelve months it proved to be.

Above all, what stands out is the unwavering commitment of our UK team. Their dedication to our shared purpose has driven everything we have accomplished this year.

It is with sadness but gratitude that we bid a fond farewell to Hasnein Alidina, my co-Managing Director, who retired at the end of 2025, after seven years with DKMS UK and a career that spanned industries as well as continents. Together, DKMS UK will continue the work that he was so committed to.

DKMS UK added 52,000 new potential life savers to the stem cell donor register in 2025, and facilitated 292 stem cell donations – exceeding our year on year performance, and giving hope to 292 patients who needed a stem cell transplant.

 52k

New potential life savers

 292

Stem cell donations



In 2025, diversifying the stem cell register was a key priority, and we committed significant resource and time in seeking to bridge the gap in access to transplants for all patients, including those whose heritage means they are less likely to find a stem cell donor match. On page 15, you can find out more about our successful 'Aunties' campaign, which was an important step towards engaging with Black and South Asian communities which are underrepresented on the stem cell donor register.

This report shares more of what we have achieved together in 2025 – and what lies ahead.

I would like to close with a message to those we are here to serve: patients, families and loved ones affected by blood cancer and blood disorders. Trust me when I say that all of us in the DKMS UK family are committed to building on this year's progress and strengthening our impact, so that everyone who needs a stem cell transplant has the best possible chance of finding a matching donor.

Thank you for your continued support.



Peter McCleave
Managing Director

01 Leo's army

Leo's story shows the power of a community pulling together to help someone in need of a life-saving stem cell transplant, and the importance of donor registration events.

Leo Sproson, from Bromsgrove, has just celebrated his 17th birthday. Late last year he was a typical, happy teenager, studying electrical engineering at a local college. One day, his mum, Jenna, noticed he was very pale and that something seemed wrong. She took him to have a blood test and was advised that evening to take Leo straight to hospital. A few days later, he was diagnosed with acute myeloid leukaemia and was told that a stem cell transplant was his best chance of survival.



No donor match was found in Leo's family, so a search began of the stem cell donor register. As this was happening, his family teamed up with DKMS UK to encourage more people to join the register. A donor registration event was organised by DKMS UK and his family in November, with an amazing 718 people signing up. The DKMS UK team organised further appeals in the media and online, which generated thousands of online requests for swab kits. So, Leo's family, community and DKMS UK all came together to help get more people on the register in support of Leo, and patients like him who are searching for a donor match.

In December, a potential donor was found for him. Leo prepared for the transplant, which included being isolated and chemotherapy for six weeks. Unfortunately, his transplant was delayed as the donor needed more medical tests. It was an agonising wait but finally, the donor was medically cleared and Leo's transplant went ahead in early 2026.

 **718**

Sign ups from donor registration event organised by DKMS



Throughout, Leo's mum and dad, Jenna and Warren, have been keeping the wider community updated on their social media, chronicling the ups and downs, the worries, and the hopes, and spreading awareness of the DKMS stem cell donor register. Leo and his family have continued to speak with media, sharing their story to encourage more people to join the register, to help save more lives like Leo's.

Already, multiple people who signed up in the November donor drive have let the family know that they have been contacted as potential donors, and are going through additional tests to confirm they are the best match. This is an amazing result – more lives could be potentially saved as a result of a single donor drive – showing the importance of these events.

After a long journey to his transplant, Leo has now been able to return home. He has a long road to recovery in front of him, but he has the love and support of his family and friends, including DKMS UK. His family's work with DKMS UK has added thousands to the register, and has the potential to give many other patients like Leo a second chance.



02 Singing along and signing up

To a soundtrack of Sting, Faithless and Clean Bandit, our dedicated volunteers were busy signing up new potential lifesavers alongside our charity partner the Love Hope Strength Foundation at last year's Isle of Wight music festival.

As part of a drive to prioritise and increase the number of younger people registered as donors on the stem cell database, DKMS UK has been raising awareness at more music festivals across the UK. Music festivals are a great way to connect with younger people, talk with them about blood cancer and disorders, and help them to register as a potential life saver.

In 2025, DKMS UK continued our partnership with the Love Hope Strength Foundation (LHS), who have supported us at festivals, concerts and other music events. We have been grateful for their continued support, especially after the sad passing of their founder, Mike Peters, in April 2025.

The biggest festival on our programme for last year was the annual Isle of Wight music festival. Together, a team from DKMS UK and LHS signed up over 500 new potential stem cell donors, mostly younger people.

 500

New potential stem cell donors
(mostly younger people)



The latest research shows that stem cell transplants from younger donors more often lead to better outcomes for the recipient patients. As such, medical teams prefer to select a younger person for a donation. DKMS UK is therefore striving to get as many younger people signed up as possible, especially under 25s, to improve the odds for patients worldwide. This will continue to be a priority next year, and in 2026 DKMS UK will be changing our age guidelines for registration, welcoming 16 year olds on to the stem cell donor register.

Through our festival programme, DKMS UK is working hard to spread awareness about blood cancers and disorders amongst young people, as well as increasing the numbers of potential younger donors on the register. While adverts and social media campaigns definitely have an impact, sometimes you need to go where potential donors are. Music festivals provide a great opportunity to connect with younger potential donors – as shown by the fantastic result the DKMS UK volunteers had at the Isle of Wight festival. 500 potential new donors on the registry? That's music to our ears!



03 A gala for hope and remembrance



Our West Midlands Volunteering Hub is one of DKMS UK’s most active volunteer groups, and in 2025 they celebrated their ten year anniversary.

To mark this milestone, our amazing volunteers hosted a fundraising gala in November. Close to £45,000 was raised, smashing their previous records.

 45k

Raised by West Midlands volunteers



The evening celebrated the hub’s achievements over the previous decade, including their outreach work in the South Asian community, but also honoured two very special people, Amilah and Bansri.

Ten year old Amilah was the guest of honour, along with her mum Mobeen. She has been diagnosed with aplastic anaemia, a very rare and life-threatening blood disorder, and her medical team has said that she may eventually need a stem cell transplant. Unfortunately, there is no donor match within her family, and because donors of her Pakistani heritage are currently underrepresented on the UK register, her chances of finding an unrelated donor match are reduced. So, Amilah’s family and DKMS UK launched a campaign to encourage more potential South Asian donors, and in 2025, she found a match! For now, her doctors are watching and waiting but, as Mobeen says:

“Knowing a donor is on standby has brought my family unbelievable relief.”
Mobeen

The West Midlands Volunteering Hub gala event was also one of remembrance. Bansri, a long-time volunteer, sadly passed away earlier in the year. After her own diagnosis of acute lymphoblastic leukaemia, Bansri became an active and well-loved member of the DKMS community. She was dedicated to DKMS UK, encouraging people to sign up to the stem cell register and touching many lives in the process. She was fondly remembered at the gala, with her husband leading the tributes to her and her work.

People from UK minority ethnic communities currently make up just 16% of the UK stem cell register. This means that patients from these backgrounds often face a longer wait to find a donor match. The West Midlands Volunteering Hub is raising awareness within their local community; with a goal to increase the number of donors on the stem cell register and give everyone, whatever their heritage, a better chance of finding a match. They have made particularly valuable connections in the South Asian community, and the outreach work that they, along with all our volunteers, do is vital to our mission to ensure everyone who needs a stem cell transplant has equal access to one.

Events like this directly fund our work, giving more people hope, more families time together, and more patients a second chance at life. With the money that was raised at the gala, many more people can be signed up to the stem cell register as potential lifesavers, giving patients like Amilah a second chance.



“Amrit delivered such a heartfelt speech, and there was not a dry eye in the room. Bansri’s story has meant so much to all of us and had a huge impact that night.”
Manj, organiser

04 Giving back during Ramadan

Lancaster University staff and students teamed up to organise a stem cell donor registration event during Ramadan. They helped colleagues and classmates understand the value of becoming a DKMS donor – while signing up more than 250 new potential lifesavers.

The university’s Health Partnerships Team began working with DKMS after colleague, Jon Powell, successfully donated stem cells, giving a patient a second chance at life. Operations Manager Jen Melling, from the Health Partnerships Team, said:

“We were inspired by Jon’s successful stem cell donation and agreed we wanted to help DKMS get their message out among university colleagues – and sign up as many potential lifesavers as possible.”

Jen Melling

Coincidentally, Lancaster medical student Eshan had also contacted DKMS to organise an event during Ramadan. He had heard that patients from UK ethnic minority groups have a much smaller chance of finding a matching donor, as they are currently underrepresented on the register.

The charity brought the staff and students together to join forces. Eshan helped recruit more than 30 volunteers from the Lancaster University Medical and Islamic societies, to work with staff and help stir the campus into action. The team organised an education session with DKMS UK, plus a massive stem cell donor registration event on campus.

With support from DKMS and the Health Partnerships Team, the student volunteers used social media and in-person events to spread the word. They posted videos on social media about DKMS UK, the stem cell register, the registration event and, most importantly, the need to get more young people, particularly those from minority heritages, signed up.

They didn’t stop there. The Islamic Society held an open Iftar, inviting students from all religious or ethnic backgrounds to join them in breaking their fast during Ramadan. Over 600 people attended, the largest open Iftar the society had ever held. It was a perfect opportunity to engage a diverse community about the importance of the stem cell donor register.



“

Ramadan is a time dedicated to doing good, being charitable, and giving back, which made it an ideal time to run a donor registration event.”

Eshan

At the registration event the next day, Lancaster University and DKMS volunteers came together and signed up over 250 new potential lifesavers: a huge achievement, bringing hope to patients who need a stem cell transplant.

In 2025, DKMS UK worked closely with college and university students, and community leaders to increase the numbers of young people, and people from UK ethnic minority groups on the stem cell donor register. This work includes our Student Ambassador and Stem Cell Society Programmes. Student Ambassadors and Stem Cell Societies engage fellow students at their college or university about the stem cell register, and why it is important for young people to sign up to be potential lifesavers. Already, we have 13 stem cell societies and 83 ambassadors, leading the way on their campuses.





05 Trekking for Amelie

Imagine walking 100 kilometres in the blistering heat, across a vast desert, over sand dunes and sand seas stretching for kilometres ahead of you. That's exactly what Sofia Flatt from Bedfordshire, and a team of intrepid DKMS fundraisers did in November 2025.

Sofia's daughter, Amelie, now 13, has had leukaemia four times in her young life and was first diagnosed when she was only a toddler. After the series of relapses, her medical team decided that her best chance at survival was to have a stem cell transplant.

In 2024, Amelie received a life-saving stem cell transplant from a total stranger, found on the donor register with the help of DKMS UK. She's now doing really well – back at school, hanging out with her friends and living life as a normal teenager. She even went to see Taylor Swift on her Eras tour – a dream come true for Amelie. This was all possible because of someone's kindness and their life-saving stem cell donation.

Sofia wanted to pay it forward, in a big way. A stranger had done some simple swabs, joined the stem cell register and – having been found to be a match for Amelie – their stem cell donation gave her a second chance at life. So, Sofia wanted to help DKMS UK sign up more people to the register, offering hope to more people like Amelie.

“I want to do something exceptional to encourage people to join the stem cell register. I'll spend the rest of my life working to get people on it – because it saved my daughter's life.”

Sofia Flatt

Sofia had previously joked that she never even walks to the shops, and hated sand so much that she didn't even let Amelie have a sand pit as a child. However, she decided to raise money and awareness for DKMS UK by taking on a major challenge, walking 100km across the Sahara desert.

In November 2025, Sofia, three friends and the rest of the DKMS Sahara trekkers team successfully traversed 100km of desert, slept under starry skies, and raised a whopping £52,000 – with Sofia and her friends raising almost £22,000. Each one of the trekkers had their own personal connection to DKMS, and together they overcame a daunting physical challenge to help support loved ones and many others diagnosed with blood cancers and disorders.

This was a huge achievement, both personally in crossing the desert, but also in terms of the massive amount of money raised. Each new person signing up to the stem cell donor register costs DKMS around £40, so Sofia and her friends raised enough to process 550 new potential donors. Her dedication shows what an impact undertaking fundraising challenges for DKMS can have, increasing the odds of more patients finding their lifesaving stem cell donor match.



06 Listen to your Aunties!

DKMS UK launched a new online and out-of-home advertising campaign, Listen to your Aunties! In September 2025 across London, Leicester and Birmingham.

The campaign worked to increase awareness of blood cancers and disorders and the stem cell donor register, and to increase the number of potential donors from the UK's Black and South Asian communities.

Blood cancers and disorders can affect anyone, regardless of ethnicity, but when patients need a stem cell transplant, they have a better chance of finding a donor match with someone who shares similar ethnic heritage.



Unfortunately, representation of UK ethnic minority communities on the stem cell donor register is very low, and this means that patients from those communities with these diagnoses experience long waits for a stem cell donor who could save their life.

Just 7% of the UK eligible population is on the stem donor cell register, and only 16% of those on it come from any minority ethnic backgrounds. So, it's not just about how many people are on the stem cell register, it's about the diversity of the registered donors. In 2025, DKMS UK worked hard to increase this, to give every patient with a relevant diagnosis an equal opportunity for a second chance at life.

To help meet this challenge, DKMS UK conducted research with the key target groups, to better understand how we could reach them. From this the new, Listen to your Aunties!, advertising campaign was created – as part of a wider DKMS UK strategy to increase the representation of ethnic minority communities on the register.

The campaign featured older women characters, the 'DKMS Aunties'. We created adverts featuring 'aunties' from Black and South Asian backgrounds, with messages for the younger people in their communities.



These included: "Ah ahhh, you don't know DKMS? Aunties are watching! Become a lifesaver" and "Good deeds, proud Aunties. They'll tell everyone. Become a lifesaver." We also created videos with the models we cast to play the Aunties, talking about DKMS and blood cancers and disorders, sharing their personal stories, and encouraging people to sign up to be a stem cell donor.

The adverts were placed at bus stops, on buses and on billboards at 250 sites across London, Birmingham and Leicester, coinciding with Blood Cancer Awareness month in September. The videos were uploaded to social media, and we worked closely with influencers from our target communities to help further spread the word online. We also created content with the DKMS team visiting advertising sites in London, talking to members of the public and spreading awareness of DKMS and the campaign.

It was a widespread campaign, using different approaches – billboards, social media, in-person events – to reach as many people as possible. The campaign was based on extensive research and insights, and played on the authority of older women in the target communities. The message was simple: more of us on the register = **more chances of saving the lives of people who share our heritage.**



07 Lucy and Harvey: a transatlantic story

When Lucy Ward, from Sleaford, was at university, she registered as a potential life saver with DKMS UK. That simple act led to Harvey’s life being saved, and a new transatlantic friendship.

Having registered as a stem cell donor as a student, Lucy was married, working in the NHS and a mum to a young daughter, when she got a call from DKMS UK in 2023 to tell her she was a match for someone who needed a transplant, and asking if she would help. She did not hesitate to say yes.



That person was Harvey Gorrin from New York State, a retired doctor, dad and granddad. He had been diagnosed with acute myelogenous leukaemia and needed a stem cell transplant.

His family had volunteered to be donors, but unfortunately, none of them were a match. This isn't unusual, only 30% of patients will find a match within their immediate families. For patients in need of a matching donor, it is usually a stranger who is able to give them a second chance. That donor could even be someone who lives in a completely different country, which is why it's so important that people around the world register as potential stem cell donors.

Lucy's donation process was handled by the DKMS UK team, and took place at Sheffield Hallam Hospital. With support from DKMS, her stem cells were immediately sent across the Atlantic, where Harvey was waiting for his transplant.

Soon after, Harvey began to feel better. He stayed in hospital for a month and then in a flat close by so he could easily go for follow-up appointments, before finally going home. Now, two years later, he's playing with his grandchildren, riding his Peloton bike and enjoying life to the full. Harvey reflects, "Lucy gave my grandchildren their grandfather. She gave my wife her husband, my children their father. Lucy gave me my life."

After his transplant, Lucy and Harvey wrote to each other anonymously, with DKMS UK acting as the go-between. They did not yet know who the other was, but they shared a special bond. After the two-year anonymity period lapsed post-transplant, they both decided they wanted to meet each other, in person.

DKMS put them in touch, and in 2025, Harvey flew from New York with his wife, daughter and grandson, to meet Lucy and her family. "There were a lot of tears – just so many happy tears when we first met!" says Lucy.

“Right away it felt like we were meeting with friends or family. It feels like we’ve got family on the other side of the world now.”

Lucy

Lucy and Harvey worked with DKMS UK to share their story, to encourage others to join the stem cell donor register. They both were amazed at how a person in one part of the world could donate stem cells to someone living in another part of the world. Their story shows how the work of DKMS is helping to treat patients with blood cancers and disorders on a global level.



DKMS Foundation:

Trustees report

Preparation of report

The company qualifies as small under section 383 of the Companies Act 2006, the strategic report required of medium and large companies under The Companies Act 2006 (Strategic Report and Director's Report) Regulations 2013 is not required.

DKMS Foundation (referred to hereinafter as 'DKMS UK') is incorporated as a charitable company limited by guarantee and is a registered charity in England and Wales, and in Scotland. It is governed by its Memorandum and Articles of Association. The activities, management, finances and strategy of the Charity are overseen by a Board of Trustees, who are also the Company Directors.

DKMS UK is connected through common Trustees to DKMS Group gGmbH ('DKMS'), and its related charities.

The Trustees who held office during the financial year and at the date of the report are set out on page 57.

A minimum of two Trustees at any one time are required by the Articles of Association. There is no maximum limit required by the Articles. At every Annual General Meeting (AGM) one-third of the Trustees retire by rotation and are eligible for re-election. There is no restriction on the term of tenure as a Trustee. Trustees do not receive remuneration for their duties.

Purpose

DKMS UK's charitable purposes are set out in its Memorandum of Association as follows:

"The preservation and protection of good health and the relief of sickness of individuals who are suffering from any kind of blood cancer."

The aims of DKMS UK are to:

- raise awareness of blood stem cell donation;
- increase the number and diversity of registered potential blood stem cell donors in the UK; and

- provide more second chances at life for those with blood cancer or blood disorders whose survival depends upon being matched with an unrelated blood stem cell donor.

Public benefit

DKMS UK raises awareness of blood cancers and blood disorders in the UK, including the life-changing impact of a diagnosis, in order that increasing numbers of the general public know about the need for more people to register as a potential blood stem cell donor. Increasing the number and diversity of potential blood stem cell donors is vital in increasing the life chances of blood cancer and disorder patients who need a blood stem cell transplant. At present, only 7% of the UK's eligible population are registered as donors compared to much higher levels in some other countries.

Registering more potential blood stem cell donors means that we are able to provide more second chances at life by finding and supporting an unrelated blood stem cell donor who can and will donate their stem cells for a patient in need of a life-saving blood stem cell transplant.

Through recruiting, registering and supporting blood stem cell donors to be part of life-saving treatments, we deliver significant public benefit to patients and their families and to the National Health Service, which arranges treatment and care for those patients.

The Trustees review the aims, objectives and activities of DKMS UK each year, ensuring the Charity remains focused on its stated purpose. This report looks at what DKMS UK has achieved and the outcomes of its work in the reporting period.

The Trustees have referred to the guidance contained in the Charity Commission's general guidance on public benefit when reviewing the Charity's aims and objectives and in planning its future activities. In particular, the Trustees consider how planned activities will contribute to the aims and objectives that have been set.

Board and management operations

The Board of Trustees meets twice a year to review DKMS UK's work, finances and services, and to agree the strategic goals for the Charity.

Recruitment and appointment of new Trustees

Trustees are appointed on the basis of their relevant skills and experience. The ongoing Trustees are responsible for the induction of any new Trustees, which involves an awareness of a Trustee's responsibilities, the governing document, administrative procedures, the history, approach and current business plan of DKMS UK.

The Trustees also make available a welcome pack to include copies of the previous year's annual report and financial statements, a brief history of the charitable company and a copy of the governing document. The pack also includes a copy of the Charity Commission guidance 'The essential Trustee: What you need to know. What you need to do.'

While DKMS UK is connected through common Trustees to DKMS Group gGmbH ('DKMS'), it continues to aim to recruit additional Trustees that can broaden and support its representation in the UK.

Management and organisation

Day-to-day operations of the Charity and strategy implementation is delegated to the Country Managers supported by the Senior Leadership Team (SLT). In the absence of the Country Managers, Stephan Schumacher, Trustee oversees the work of the SLT.

The Senior Leadership Team comprises:

- Country Managers Hasnein Alidina and Peter McCleave
- Head of Communications and Engagement Daniel Philipp Hoffmann

- Head of Finance Margaret Brett
- Head of Fundraising Caroline Richardson
- Head of Donor Support Services Josh Winters
- HR Manager Lisa Karlsson
- Head of Donor Recruitment Hannah Tarrant
- Head of Donor Request Management Sam McIntyre
- Head of Quality Risk and Control Suzana Drummond

Related parties

The only related parties are considered to be the Trustees and those connected with the Trustees, including their close family, business and other charity interests. There have been no transactions with related parties, other than the reimbursement of reasonable travel expenses for the purposes of attendance at Board meetings and other relevant organisational activities.

Remuneration

In order to recruit and retain staff of the calibre it requires, DKMS UK's pay policy is to remunerate staff at levels above the voluntary sector median rate, but below the private sector market rate. The Charity has an organisational salary structure based upon a job evaluation study and external salary benchmarking concluded in June 2023. New roles are assessed against the job evaluation criteria and placed in a corresponding grade in the structure.

The salary structure's pay levels are reviewed at least annually by the Country Managers to ensure that salary scales are aligned with those for similar positions in the external market. A review of salaries normally takes place annually, and is usually implemented in January. If changes are to be made, staff are advised in writing of the amount and the date from which it takes effect. A salary review does not imply an increase and in making any pay award the review will be based on the organisation's financial health and achievements.

With reference to the National Council of Voluntary Organisation's 2014 inquiry into executive pay (NCVO, Report of the Inquiry into Charity Senior Executive Pay and Guidance for Trustees on Setting Remuneration), the Board of Trustees is committed to including the following information within its annual statutory report and financial statements:

- A summary statement of the Charity's remuneration policy and approach to senior executive pay.
- Disclosures on the number of staff in receipt of more than £60,000 per annum (in bands of £10,000), and the collective total benefits (including pension payments and employer's national insurance) paid to 'key management personnel' (which we have defined as the Senior Leadership Team), in line with the accounting Statement of Recommended Practice 2019 for charities. Given the Charity's size, the Board of Trustees does not believe it is appropriate to disclose the actual/personal salary of any individual member of staff including senior executives, to the public.
- Disclosures on pensions and other staff benefits (see subsequent notes to the financial statements).

Our approach to fundraising

We continue to uphold the highest standards in how we communicate with our fundraising donors and supporters and ensure that our fundraising practices meet the requirements of the recommended Codes of Practice.

We treat our donors and supporters with great respect and gratitude that befits a community of people and organisations that make our work possible.

Key aspects of our approach to fundraising include:

- Registration with the Fundraising Regulator, which maintains the standards for charitable fundraising and ensures that fundraising is respectful, open, honest and accountable to the public. It also takes complaints about fundraising, investigates cases and adjudicates on fundraising practice.
- Ensuring our fundraising approach is aligned with the Charity's governing objectives.
- We have a complaints policy, which outlines our commitment to resolving fundraising complaints as promptly and amicably as possible. It also sets out our process for handling any complaints received.

As per our policy, complaints will be reported and referred to the Fundraising Regulator if a resolution with the complainant cannot be reached or if the complaint is about a breach of any aspect of the Code of Fundraising Practice.

- In 2025 we did not receive any complaints across the organisation. Trustees are updated on a bi-annual basis with regards to the number of complaints we have handled in the year.
- We raise funds through individual giving requests (cash appeals, regular donation asks and online giving), community, challenge events, corporate and trust fundraising.
- We do not carry out any telephone, face-to-face or door-to-door fundraising.
- We do not use third party agencies to make fundraising requests, although we do use them for fulfilment purposes, e.g. acquisition of charity place challenge events, processing direct debits or distribution of fundraising direct mail. In such situations, legal agreements are in place. In no other circumstance do we swap or share data and we never sell data.
- All fundraising activity complies with the UK General Data Protection Regulation (GDPR) and associated legislation and guidance.
- Promotional goods sent out for fundraising purposes, and use of our logo on external fundraising materials, is subject to approval. Official stationery, such as our letterhead, is never sent out for external use.

Risk assessment and management

DKMS UK operates a risk assessment and management framework that reviews major risk areas on a quarterly basis.

The Country Managers and individual members of the SLT take responsibility for the day-to-day management and oversight of the above risk areas. The Trustees review the assessments and mitigating actions at their Board meetings and consider the following areas to be the major risks related to DKMS UK's operations and activities.

Medical safety of donors during the blood stem cell collection process

Although the medical process and procedure for blood stem cell donation and collection is safe, well-established and regulated, there will always be some safety risks and DKMS UK acknowledges these and takes them seriously.

The risks to the safety of our donors before, during and after the donation process, as well as any risks to transplant patients from the collection of poor-quality stem cell product are managed and mitigated in the following ways:

- Working in line with approved and regularly reviewed Standard Operating Procedures that comply with domestic and international standards and regulations, and that include clear identification and reporting mechanisms for Serious Adverse Events and Reactions and Quality Incidents.
- Working only with experienced, trusted and appropriately regulated medical partners and services. These relationships in turn are governed via established legal contracts and service protocols and regular service reviews.
- Ensuring a thorough quality assurance system is in place within the organisation, including compliance with the World Marrow Donor Association (WMDA) standards (qualification for which was achieved and approved in March 2021).
- Ensuring ongoing training, support and continuing professional development for all staff involved in the blood stem cell registration and donation process.

Data management and protection

The collection, processing, storage and security of our blood stem cell donors' personal data and genetic information is of paramount importance and so represents a major risk in the event of mismanagement, loss or misuse of that data.

The potential damage to individual donors through a data breach, let alone the damage to DKMS UK's and the DKMS Group's reputation and activities in working with patients, donors, supporters and stakeholders would be catastrophic.

We manage and mitigate these risks through:

- Adherence to and compliance with strong information security and data protection policies and practices throughout the whole DKMS Group.
- Ensuring data processing and third parties and protocols are in place with suppliers and partners.
- Regular training and reviews for staff, volunteers and donor registration partners.
- Blood stem cell donor recruitment.

Effective and high-quality blood stem cell donor recruitment is essential to ensuring we meet the needs of patients and transplant centres looking for a match. If we fail to ensure we recruit sufficient numbers of donors with a diverse range of backgrounds, and

also with accurate and regularly updated personal health and genetic information and contact details, then we risk not being able to save the lives of more blood cancer and blood disorder patients. We manage and mitigate this risk by ensuring we have:

- Clear and compelling communications and explanations about the registration process and the need for blood stem cell donors.
- Effective quality check and review processes.
- Quality programmes to enhance the health and contact information we have on the priority groups among our blood stem cell donors.
- A system for prioritisation for recruiting, retaining and supporting potential and actual blood stem cell donors.

Financial risks

There are a number of areas of financial risk faced by DKMS UK:

- Failure to achieve budgeted income levels.
- Inadequate financial controls or fraud.
- Poor financial management, including credit risk management, pricing risk and foreign exchange and liquidity risks.

These risks are managed and mitigated in the following ways:

- Strong planning, budgeting and monitoring processes in relation to income streams, including fundraising.
- Strong internal financial controls and data security.
- Regular reviews of fraud risks.
- Close interaction, support and cross-checking with the international financial management and controlling teams in Germany.
- Vetting by DKMS Germany of international health services, registries and companies involved in stem cell transplantation, so that stringent assessments on credit risk are carried out and appropriate financial terms agreed for all DKMS companies within the Group.
- Ensuring pricing of products and services is set at reasonable and affordable levels, that recognise the Group's role as a healthcare service provider with a primary objective of saving lives. Pricing levels are based on a production cost structure and also acknowledge differences in international economies, as well as the need to ensure patient treatments are not jeopardised by costs.

- Maintaining good cash flow and financial management systems in order to manage fluctuations in the major trading currencies in which DKMS UK deals.
- Cash flow projections are prepared as part of the Charity's strategic planning, while liquidity levels are monitored internally on a daily basis as well as reported to central management and Trustees at each reporting period.
- Adequate balances are maintained in all currencies to ensure sufficient funding is available to meet commitments.

Logistical and supply line business continuity and resilience

Ensuring we have reliable, efficient and cost-effective methods for transporting our swab packs, blood samples and collected blood stem cells is crucial to the successful achievement of our organisational goals and objectives to save more lives, as is having a well-stocked and maintained supply line, resources and medicines. To manage and mitigate the risks of business-critical supplies and logistical arrangements we have:

- Implemented strong review processes for stock control and order processing.
- Made alternative arrangements and contingency plans for business continuity and disaster recovery scenarios.
- Developed contingency plans to provide for business periods where we are working at higher than normal levels of activity or volume (e.g. when running successful campaigns).

UK's economic challenges and its effects on DKMS UK business activities

The UK economy in common with almost all countries in the world experienced a sharp increase in the cost of living with inflation reaching over 11% for a short period in late 2022. The Bank of England and the UK government implemented various economic policies to prevent the inflation rate imbedding in the economy and spiralling out of control. Fall in energy prices and good economic governance has resulted in reducing UK's inflation rate to about 2.5% by mid-2024. The UK economic outlook now appears more positive and predictable. However significant part of the cost increases cannot be passed on and are therefore absorbed by the charity. The UK inflation rate remains at 3.8%

Financial review

Going concern

The Board of Trustees of the ultimate parent company approved an arrangement to continue funding DKMS UK's main activities to meet all its liabilities from its principal, DKMS Group gGmbH for a period not less than 12 months from the date these financial statements are approved. Accordingly, the Trustees continue to adopt a going concern basis in preparing the financial statements.

The company's business activities in 2025 show positive results to budget and the trend is expected to continue for rest of the year with the company's funding requirements expected to remain well within the amounts approved by the board for next three years.

The charitable company's net current assets at 31 December 2025 were £3,431,585 (2024: £2,659,153). Further details regarding the adoption of the going concern basis can also be found in the Accounting Policies on page 32.

Financial results

DKMS UK received donations totalling £7,259,523 (2024: £4,817,209) of which £3,240,511, (2024: £3,025,173) was donated funds, £4,019,012 (2024: £1,792,036) was donated services from DKMS in Germany.

The charity company's net income for the year amounted to £272,432 (2024: -£28,759) The increase in net income was influenced by an increase in funding for donor recruitment activities.

Reserves policy

DKMS UK's aim is to gradually grow its unrestricted funds and achieve full financial independence. While the Charity is growing its income base and cash flow, it continues to receive funding for its main activities from its principal, DKMS Group gGmbH. The Trustees have approved for this arrangement to continue for the foreseeable future and until DKMS UK becomes financially independent to meet all its liabilities for at least 12 months. As at 31 December 2025 DKMS UK's unrestricted funds were £2,931,585 (2024: £2,659,183).

Principal funding

In the period under review, DKMS UK's significant funding comes from donations from DKMS Group in Germany. In the meantime, the charitable company continues to grow its fee income from referral of

potential blood stem cell donors and management of peripheral blood stem cell or bone marrow collections and establishing a broader base of additional funding sources to grow its voluntary donation income.

The charity has also developed a fundraising strategy to raise additional funding through new voluntary donations initiatives and events.

Future developments

DKMS remains focussed on achieving steady growth in number of stem cell donations.

We are aware that our donation volume may show some reduction over next 2-3 years as we refocus on increasing our donor pool of young and preferred aged donor group.

Recruitment must remain targeted, with a particular focus on young donors and from ethnic minority communities, as those groups will further help increase our overall number of matched donors, and move us closer to levelling up access to transplantation in these communities.

Fundraising work is planned to grow significantly over the next three years to support our expansion, with important areas for future growth being community-based and volunteer-led programmes, along with an expanded corporate support programme. This support is vital to achieve our aim of finding a matching donor for every stem cell transplant patient that needs one and where required covering the costs of the transplant.

Sustainability

In 2025 DKMS UK published our first Environmental Policy, marking an important step in our commitment to advancing our Environmental Social Governance agenda by ensuring we take responsibility for understanding, managing, and reducing the impact of our own operations. We will continue to collaborate closely with our providers and partners to ensure ESG is embedded in our work, with a particular focus on minimising our impact and promoting sustainability, helping to measure, offset, and reduce the environmental impact associated with our activities.

Change of trustees and directors

Dr A H Schmidt resigned as Trustee on 22nd January 2025.

Trustees' responsibilities statement

The Trustees (who are also directors of DKMS Foundation for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice).

Company law requires the Trustees to prepare financial statements for each financial year. Under company law the Trustees must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the charitable company and of the incoming resources and application of resources, including the income and expenditure, of the charitable company for that period.

In preparing these financial statements, the Trustees are required to:


- select suitable accounting policies and then apply them consistently;
- observe the methods and principles in the Charities Statement of Recommended Practice (SORP);
- make judgments and accounting estimates that are reasonable and prudent;
- prepare the financial statements on the going concern basis unless it is inappropriate to presume that the charitable company will continue in operation.

Disclosure of information to auditors

Each of the persons who are Trustees at the time when this Trustees' report is approved has confirmed that:

- so far as that Trustee is aware, there is no relevant audit information of which the charitable company's auditors are unaware, and
- that Trustee has taken all the steps that ought to have been taken as a Trustee in order to be aware of any relevant audit information and to establish that the charitable company's auditors are aware of that information.

This report was approved by the Trustees and signed on their behalf by:

Signiert von:

 CA077F0D9BC0497...
Bernd Weinel
 Trustee

26 September 2026

DKMS Foundation: Independent auditors' report to the members and trustees of DKMS Foundation

Opinion

In our opinion, DKMS Foundation's financial statements (the 'financial statements'):

- give a true and fair view of the state of the charitable company's affairs as at 31 December 2025 and of its incoming resources and application of resources, including its income and expenditure, and cash flows for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice (United Kingdom Accounting Standards, comprising FRS 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland', and applicable law); and
- have been prepared in accordance with the requirements of the Companies Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended).

We have audited the financial statements, included within the Annual Report and Financial Statements (the 'Annual Report'), which comprise: the balance sheet as at 31 December 2025; the statement of financial activities (incorporating income and expenditure account) and the statement of cashflows for the year then ended; and the notes to the financial statements, which include a description of the significant accounting policies.

Basis for opinion

We conducted our audit in accordance with International Standards on Auditing (UK) ('ISAs (UK)') and applicable law. Our responsibilities under ISAs (UK) are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

Independence

We remained independent of the charitable company in accordance with the ethical requirements that are relevant to our audit of the financial statements in the UK, which includes the FRC's Ethical Standard and we have fulfilled our other ethical responsibilities in accordance with these requirements.

Conclusions relating to going concern

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the charitable company's ability to continue as a going concern for a period of at least twelve months from the date on which the financial statements are authorised for issue.

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

However, because not all future events or conditions can be predicted, this conclusion is not a guarantee as to the charitable company's ability to continue as a going concern.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

Reporting on other information

The other information comprises all of the information in the Annual Report other than the financial statements and our auditors' report thereon. The Trustees are responsible for the other information. Our opinion on the financial statements does not cover the other information and, accordingly, we do not express an audit opinion or, except to the extent otherwise explicitly stated in this report, any form of assurance thereon.

In connection with our audit of the financial statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the audit, or otherwise appears to be materially misstated. If we identify an apparent material inconsistency or material misstatement, we are required to perform procedures to conclude whether there is a material misstatement of the financial statements or a material misstatement of the other information.

If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact. We have nothing to report based on these responsibilities.

With respect to the Trustees' Report, we also considered whether the disclosures required by the UK Companies Act 2006 have been included.

Based on our work undertaken in the course of the audit, the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) require us also to report certain opinions and matters as described on the next page.

Trustees' Report

In our opinion, based on the work undertaken in the course of the audit the information given in the Trustees' Report for the financial year for which the financial statements are prepared is consistent with the financial statements and the Trustees' Report have been prepared in accordance with applicable legal requirements.

In addition, in light of the knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we are required to report if we have identified any material misstatements in the Trustees' Report. We have nothing to report in this respect.

Responsibilities for the financial statements and the audit

Responsibilities of the Trustees for the financial statements

As explained more fully in the Trustees' Responsibilities statement, the Trustees are responsible for the preparation of the financial statements in accordance with the applicable framework and for being satisfied that they give a true and fair view. The Trustees are also responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the charitable company's ability to continue as a going concern, disclosing as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the charitable company or to cease operations, or have no realistic alternative but to do so.

Auditors' responsibilities for the audit of the financial statements

We have been appointed as auditors under section 44(1) of the Charities and Trustee Investment (Scotland) Act 2005 and under the Companies Act 2006 and report in accordance with the Acts and relevant regulations made or having effect there under.

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion.

Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non-compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud, is detailed below.

Based on our understanding of the charitable company and industry, we identified that the principal risks of non-compliance with laws and regulations related to Health and Safety regulations and employment law, and we considered the extent to which non-compliance might have a material effect on the financial statements. We also considered those laws and regulations that have a direct impact on the financial statements such as the Companies

Act 2006, the Charities and Trustee Investment (Scotland) Act 2005 and regulation 8 of The Charities Accounts (Scotland) Regulations 2006 (as amended). We evaluated management's incentives and opportunities for fraudulent manipulation of the financial statements (including the risk of override of controls), and determined that the principal risks were related to manipulation of financial performance. Audit procedures performed included:

- Enquiries of management around known or suspected instances of non-compliance with laws and regulations, claims, litigation, and instances of fraud;
- Understanding of management's controls designed to prevent and detect irregularities;
- Review of board minutes;
- Identifying and testing journal entries to assess whether any of the journals appeared unusual, for example unexpected account combinations impacting revenue; and
- Incorporating an element of unpredictability into our testing plan.

There are inherent limitations in the audit procedures described above. We are less likely to become aware of instances of non-compliance with laws and regulations that are not closely related to events and transactions reflected in the financial statements. Also, the risk of not detecting a material misstatement due to fraud is higher than the risk of not detecting one resulting from error, as fraud may involve deliberate concealment by, for example, forgery or intentional misrepresentations, or through collusion.

A further description of our responsibilities for the audit of the financial statements is located on the FRC's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our auditors' report.

Use of this report

This report, including the opinions, has been prepared for and only for the charitable company's members and Trustees as a body in accordance with section 44(1)(c) of the Charities and Trustee Investment (Scotland) Act 2005 and the Companies Act 2006 and regulations made under those Acts (regulation

10 of The Charities Accounts (Scotland) Regulations 2006 (as amended) and Chapter 3 of Part 16 of the Companies Act 2006) and for no other purpose. We do not, in giving these opinions, accept or assume responsibility for any other purpose or to any other person to whom this report is shown or into whose hands it may come save where expressly agreed by our prior consent in writing.

Other required reporting

Matters on which we are required to report by exception

Under the Companies Act 2006 and The Charities Accounts (Scotland) Regulations 2006 (as amended) we are required to report to you if, in our opinion:


- we have not obtained all the information and explanations we require for our audit; or
- adequate and proper accounting records have not been kept or returns adequate for our audit have not been received from branches not visited by us; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- the financial statements are not in agreement with the accounting records and returns.

We have no exceptions to report arising from this responsibility.

Entitlement to exemptions

Under the Companies Act 2006 we are required to report to you if, in our opinion, the Trustees were not entitled to: prepare financial statements in accordance with the small companies' regime and take advantage of the small company's exemption from preparing a Strategic Report.

We have no exceptions to report arising from this responsibility.


Nicola Wakefield (Senior Statutory Auditor) for and on behalf of Forvis Mazars LLP Chartered Accountants and Statutory Auditors, Sutton Court Road, Sutton, Surrey, SM1 4FS

28 September 2026



DKMS Foundation:

Statement of financial activities

(Incorporating income and expenditure account)
for the year ended 31 December 2025

		Unrestricted funds 2025	Total funds 2025	Total funds 2024
	Note	£	£	£
Income from				
Donations and legacies	2	7,259,523	7,259,523	4,817,209
Charitable activities	3	7,631,975	7,631,975	8,079,045
Total Income		14,891,498	14,891,498	12,896,254
Expenditure on				
Raising funds	4	1,434,114	1,434,114	1,317,842
Charitable activities	5, 6 and 9	13,980,340	13,980,340	12,571,825
	7, 19	15,414,454	15,414,454	13,889,667
Net income / (expenditure) before prior year VAT adjustments other recognised gains and losses		-522,956	-522,956	-993,413
Net income relating to prior year VAT treatment change	12	795,388	795,388	964,654
Net income / (expenditure) before other recognised gains and losses		272,432	272,432	-28,759
Reconciliation of funds				
Total funds brought forward		2,659,153	2,659,153	2,687,912
Total funds carried forward		2,931,585	2,931,585	2,659,153

All activities relate to continuing operations. The unrestricted funds above includes £224,407 of income (2024:£227,554) and £224,407 of expenditure (2024:£227,554) that is restricted to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

The notes on pages 22 to 41 form part of these financial statements.

DKMS Foundation:

Balance Sheet

As at 31 December 2025


		2025	2024
	Note	£	£
Fixed assets			
Tangible assets	13	208,549	248,325
Investments	14	1	1
		208,550	248,326
Current assets			
Inventory	15	114,697	60,688
Debtors	16	3,555,530	2,924,811
Cash at bank and in hand	22	446,975	887,731
		4,117,202	3,873,230
Creditors: amounts falling due within one year	17	(1,394,167)	(1,462,403)
Net current assets		2,723,035	2,410,827
Net assets		2,931,585	2,659,153
Charity Funds			
Unrestricted funds	19	2,931,585	2,659,153
Total funds	20	2,931,585	2,659,153

The company's financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The trustees consider that the company is entitled to exemption from the requirement to have an audit under the provisions of section 477 of the Companies Act 2006 ("the Act") and members have not required the company to obtain an audit for the year in question in accordance with section 476 of the Act. However, an audit is required in accordance with section 144 of the Charities Act 2011.

The trustees acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of financial statements.

The financial statements were approved and authorised for issue by the trustees.

Signiert von:

CA037E098BC0497...
Bernd Weinel
Trustee

26 September 2026

The notes on pages 36 to 55 form part of these financial statements.

DKMS Foundation: Statement of cash flows

For the year ended 31 December 2025

		2025	2024
	Note	£	£
Cash flows from operating activities			
Net cash provided by operating activities	21	(395,346)	(765,684)
Cash flows from investing activities			
Purchase of tangible fixed assets		(45,410)	(278,640)
Net cash used in investing activities		(45,410)	(278,640)
Change in cash and cash equivalents in the year		(440,756)	1,044,324
Cash and cash equivalents brought forward		887,731	1,932,055
Cash and cash equivalents carried forward	22	446,975	887,731

The notes on pages 22 to 41 form part of these financial statements.

DKMS Foundation: Notes to the financial statements for the year ended 31 December 2025

01. Accounting Policies

1.1 Basis of preparation of financial statements

The financial statements have been prepared in accordance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) (effective 1 January 2019) - (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) and the Companies Act 2006.

DKMS Foundation meets the definition of a public benefit entity under FRS 102. Assets and liabilities are initially recognised at historical cost or transaction value unless otherwise stated in the relevant accounting policy.

The financial statements are presented in pound sterling (£).

1.2 Going concern

The trustees of the ultimate parent company review the company's activities and 3 year business plan each year and establish and approve the funding level required to enable the company to achieve its goals and meet its business commitments and liabilities.

The Trustees have approved an arrangement to continue funding the charitable company's main activities from its principal, DKMS Group gGmbH until the company becomes financially independent to meet all its liabilities for a period not less than twelve months from the date these financial statements are approved. Accordingly, they continue to adopt the going concern basis in preparing the financial statements.

1.3 Company status

The charitable company is limited by guarantee. The members of the company are the trustees named on page 57. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

1.4 Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of the company and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors or which have been raised by the company for particular purposes. The costs of raising and administering such funds are charged against the specific fund. The aim and use of each restricted fund is set out in the notes to the financial statements.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

1.5 Income

All income is recognised once the charitable company has entitlement to the income, it is probable that the income will be received and the amount of income receivable can be measured reliably. Money donation income is recognised when the income is credited into the company's account and revenue for clinical services is recognised after services are delivered.

Donated services or facilities are recognised when the charitable company has control over the item, any conditions associated with the donated item have been met, the receipt of economic benefit from the use by the charitable company of the item is probable and that economic benefit can be measured reliably. In accordance with the Charities SORP (FRS 102). General volunteer time is not recognised. Further information about volunteer contribution is included in the trustees' report.

On receipt, donated professional services and donated facilities are recognised on the basis of the value of the gift to the charitable company which is the amount the charitable company would have been willing to pay to obtain services or facilities of equivalent economic benefit on the open market; a corresponding amount is then recognised in expenditure in the period of receipt.

Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation.

1.6 Expenditure

Expenditure is recognised once there is a legal or constructive obligation to make payment to a third party, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated to the applicable expenditure headings:

- Costs of generating funds comprise the costs associated with attracting voluntary income.
- Charitable expenditure comprises those costs incurred by the charitable company in the delivery of its activities and services for its beneficiaries. It includes both costs that can be allocated directly to such activities and those costs of an indirect nature necessary to support them.
- Governance costs include those costs associated with meeting the constitutional and statutory requirements of the charitable company and include the audit fees and costs linked to the strategic management of the charitable company.
- All costs are allocated between the expenditure categories of the statement of financial activities on a basis designed to reflect the use of the resource. Costs relating to a particular activity are allocated directly; others are apportioned on an appropriate basis. Staff costs are allocated based on staff numbers, premises costs are allocated based on space occupied.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

1.7 Tangible fixed assets
and depreciation

Tangible fixed assets are carried at cost, net of accumulated depreciation and any provision for impairment. Depreciation is provided at rates calculated to write off the cost of fixed assets, less their estimated residual value, over their expected useful lives on the following bases:

- Leasehold improvements - over period of lease straight line.
- Office equipment - 33.33% per annum straight line.
- Computer equipment - 33.33% per annum straight line.

1.8 Investments

Investments are a form of basic financial instrument and are initially recognised at their transaction value. Investments in subsidiary companies are stated at cost less diminution in value.

1.9 Interest receivable

Interest on funds held on deposit is included when receivable and the amount can be measured reliably by the company; this is normally upon notification of the interest paid or payable by the Bank.

1.10 Debtors

Trade and other debtors are recognised at the settlement amount after any trade discount offered. Prepayments are valued at the amount prepaid net of any trade discounts due.

1.11 Cash at bank and in hand

Cash at bank and in hand includes cash and short term highly liquid investments with a short maturity of three months or less from the date of acquisition or opening of the deposit or similar account.

1.12 Creditors and provisions

Creditors and provisions are recognised where the charitable company has a present obligation resulting from a past event that will probably result in the transfer of funds to a third party and the amount due to settle the obligation can be measured or estimated reliably. Creditors and provisions are normally recognised at their settlement amount after allowing for any trade discounts due.

1.13 Pensions

The charitable company operates a defined contribution pension scheme and the pension charge represents the amount payable by the charitable company in respect of the year.

1.14 Financial instruments

The charitable company has applied Sections 11 and 12 of (FRS 102) in respect of financial instruments.

Financial assets and financial liabilities are recognised when the charitable company becomes party to the contractual provisions of the instrument. Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the charitable company after deducting all of its liabilities.

The charitable company's policies for its major classes of financial assets and financial liabilities are set out below.

Financial assets

Basic financial assets, including trade and other debtors, cash and bank balances, related charity working capital balances, and related charity financing are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Such assets are subsequently carried at amortised cost using the effective interest method, less any impairment.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

Financial liabilities

Basic financial liabilities, including trade and other creditors, bank loans and loans from related charities, are initially recognised at transaction price, unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest for a similar debt instrument. Financing transactions are those in which payment is deferred beyond normal business terms or is financed at a rate of interest that is not a market rate.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Impairment of financial assets

Financial assets measured at cost and amortised cost are assessed at the end of each reporting period for objective evidence of impairment. If objective evidence of impairment is found, an impairment loss is recognised in the profit and loss account.

For financial assets measured at cost less impairment, the impairment loss is measured as the difference between the asset's carrying amount and the best estimate of the amount the charitable company would receive for the asset if it were to be sold at the reporting date.

For financial assets measured at amortised cost, the impairment loss is measured as the difference between the asset's carrying amount and the present value of estimated cash flows discounted at the asset's original effective interest rate. If the financial asset has a variable interest rate, the discount rate for measuring any impairment loss is the current effective interest rate determined under the contract.

If there is a decrease in the impairment loss arising from an event occurring after the impairment was recognised, the impairment is reversed. The reversal is such that the current carrying amount does not exceed what the carrying amount would have been had the impairment not previously been recognised. The impairment reversal is recognised in profit or loss.

Derecognition of financial assets and financial liabilities

Financial assets are derecognised when (a) the contractual rights to the cash flows from the asset expire or are settled, or (b) substantially all the risks and rewards of the ownership of the asset are transferred to another party or (c) despite having retained some significant risks and rewards of ownership, control of the asset has been transferred to another party who has the practical ability to unilaterally sell the asset to an unrelated third party without imposing additional restrictions.

Financial liabilities are derecognised when the liability is extinguished, that is when the contractual obligation is discharged, cancelled or expires.

1.15 Critical accounting estimates and areas of judgment

Management does not consider there to be any key judgements or estimates made in the preparation of the financial statements.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

02. Donations and legacies

	Unrestricted funds 2025	Total funds 2025	Total funds 2024
	£	£	£
Donation income	2,141,295	2,141,295	1,963,061
International donation income	1,099,216	1,099,216	1,062,112
Funding for donor recruitment activities from DKMS Gemeinnutzige GmbH	4,019,012	4,019,012	1,792,036
Other income	-	-	-
Total donations and legacies	7,259,523	7,259,523	4,817,209
Total 2024	4,817,209	4,817,209	

Donation income includes £227,554 (2023 £175,000) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

03. Charitable activities

	Unrestricted funds 2025	Total funds 2025	Total funds 2024
	£	£	£
Income from service provision	7,631,975	7,631,975	8,079,045
Total 2024	8,079,045	8,079,045	

In the year ended 31 December 2025 and 2024 all income related to unrestricted funds.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

04. Raising funds

	Unrestricted funds 2025	Total funds 2025	Total funds 2024
	£	£	£
Salaries, national insurance and pensions	470,934	470,934	433,322
Other staff costs and training	23,690	23,690	22,689
Premises costs	61,616	61,616	65,546
Publicity & Awareness costs	735,202	735,202	586,347
Postage, support and stationery	2,896	2,896	3,396
Other admin costs	114,432	114,432	174,340
Travel costs	7,120	7,120	5,995
Loss on foreign exchange	6,338	6,338	18,495
Depreciation	11,886	11,886	7,712
	1,434,114	1,434,114	1,317,842
Total 2024	1,317,842	1,317,842	

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

05. Direct costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2025	Total 2024
	£	£	£	£	£
Other direct costs	151,080	198,722	3,230,902	3,580,704	3,847,805
International donor projects - ATT - India - Africa	1,880,542	1,115,465	-	2,996,007	2,784,551
Other staff costs and training	1,251	2,807	39,769	43,827	(4,554)
Premises cost	66,654	106,689	117,373	290,716	312,557
Publicity cost	84,663	379,866	17,523	482,052	359,144
Loss on foreign exchange	6,289	6,289	13,277	25,855	76,266
Postage, support and stationery	204,719	229,743	1,074,449	1,508,911	464,966
Travel costs	52,006	14,346	9,735	76,087	57,981
Donor typing costs	1,099,216	-	-	1,099,216	1,062,112
Salaries, national insurance and pensions	471,626	488,802	1,025,891	1,986,319	1,613,862
Depreciation	11,795	11,795	24,900	48,490	31,801
	4,029,841	2,554,524	5,553,819	12,138,184	10,606,491
Total 2024	3,020,508	2,714,587	4,871,396	10,606,491	

Direct costs includes £224,407(2024 £227,554) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

06. Support costs

	Recruitment of Donors	Raising Awareness	Donor Request Management	Total 2025	Total 2024
	£	£	£	£	£
Legal and professional fees	32,083	54,958	54,394	141,435	103,631
Loss on foreign exchange	3,218	3,217	6,793	13,228	31,621
Other staff costs and training	18,713	18,713	39,505	76,931	127,047
Premises costs	23,621	40,464	40,048	104,133	106,241
Travel costs	2,864	2,864	6,046	11,774	11,626
Other support costs	56,643	56,643	166,343	279,629	528,541
Postage, support and stationery	1,237	1,237	2,612	5,086	2,450
Admin costs	479	479	1,011	1,969	(6,893)
Salaries, national insurance and pensions	279,469	279,469	589,990	1,148,928	998,760
Depreciation	6,035	6,035	12,740	24,810	13,186
	424,362	464,079	919,482	1,807,923	1,916,210
Total 2024	426,938	460,882	1,028,390	1,916,210	

In the year ended 31 December 2025 and 2024 all expenditure related to unrestricted funds.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

07. Analysis of expenditure by expenditure type

	Staff Costs 2025	Depreciation 2025	Other Costs 2025	Total 2025	Total 2024
	£	£	£	£	£
Expenditure on raising voluntary income	470,934	11,886	951,294	1,434,114	1,317,842
Costs of raising funds	470,934	11,886	951,294	1,434,114	1,317,842
Recruitment of donors	751,096	17,830	3,685,277	4,454,203	3,447,446
Raising awareness	768,270	17,830	2,232,503	3,018,603	3,175,470
Donor request management	1,615,881	37,640	4,819,780	6,473,301	5,899,785
Charitable activities	3,135,247	73,300	10,737,560	13,946,107	12,522,701
Expenditure on governance	0	0	34,233	34,233	49,124
Total 2025	3,606,181	85,186	11,723,087	15,414,454	13,889,667
Total 2024	3,045,944	52,699	10,791,024	13,889,667	

Direct costs includes £224,407(2024 £227,554) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

Expenditure on raising voluntary income has not been allocated to specific activities as all costs relate to general charitable activities.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

08. Analysis of expenditure by activities

	Activities undertaken directly 2025	Support costs 2025	Total 2025	Total 2024
	£	£	£	£
Recruitment of donors	4,029,841	424,362	4,454,203	3,447,446
Raising awareness	2,554,524	464,079	3,018,603	3,175,469
Donor request management	5,553,819	919,482	6,473,301	5,899,786
Total 2025	12,138,184	1,807,923	13,946,107	12,522,701
Total 2024	10,606,491	1,916,210	12,522,701	

Direct costs includes £224,407(2024 £227,554) collected to fund blood cancer treatment costs for children in Africa and India and funding for nurses education and training in the UK.

09. Governance costs

	Unrestricted funds 2025	Total funds 2025	Total funds 2024
	£	£	£
Auditors' remuneration	26,650	26,650	25,750
Legal and professional fees	7,583	7,583	23,374
Total	34,233	34,233	49,124

In the year ended 31 December 2025 and 2024 all costs of direct charitable activities related to unrestricted funds.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

10. Net resources expended

This is stated after charging:

	2025	2024
	£	£
Depreciation of tangible fixed assets		
- Owned by the charity	85,186	52,699
Auditors' remuneration - audit	26,650	25,750
- Non-audit services Taxation advice	28,947	31,100

During the year, no trustees received any remuneration (2024- £Nil).
During the year, no trustees received any benefits in kind (2024 - £Nil).
During the year, no trustees received any reimbursement of expenses (2024 - £Nil).

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

11. Staff Costs

Staff costs were as follows:

	2025	2024
	£	£
Salaries	3,086,945	2,645,831
Social security costs	360,802	263,127
Pension costs	129,045	103,519
Total	3,576,792	3,012,477

The average monthly number of employees was: 65 (2024: 58)

Full time equivalents (including part-time and fixed period temporary staff): 64.55 (2024: 57.55):

	2025	2024
	No.	No.
Donor recruitment	9	8
Fundraising	6	6
Communications	9	8
Medical	19	19
Administration	9	8
Donor Service	6	6
Charity activity development	7	3
Total	65	58

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

The number of higher paid employees was:

	2025	2024
	No.	No.
In the band £60,001 - £70,000	5	4
In the band £70,001 - £80,000	4	3
In the band £80,001 - £90,000	2	0
In the band £90,001 - £100,000	0	0
In the band £100,001 - £110,000	1	1
In the band £110,001 - £120,000	0	0
In the band £120,001 - £130,000	1	0
In the band £130,001 - £140,000	0	0
In the band £140,001 - £150,000	0	1
In the band £150,001 - £160,000	0	0
In the band £160,001 - £170,000	1	0
Total	14	9

The charitable company trustees were not paid or received any other benefits from employment with the charitable company in the year (2024: £Nil) neither were they reimbursed expenses during the year (2024: £Nil). No charitable company trustee received payment for professional or other services supplied to the charitable company (2024: £Nil)

The key management personnel of the charitable company are the trustees, the Chief Executive Officer, the heads of departments and team leads. There are 12 heads of department and team leads (2024: 11), ten of whom received remuneration in excess of £60,000 during the year (2024: 9). The total employee benefits of the key management personnel of the charitable company were £1,035,629 (2024: £927,942).

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

12. Net income relating to prior year VAT treatment change

The adjustment relates to net VAT charge following change in the charity's VAT status from a change in Stem cell collection process in 2020. Output VAT of £795,388 is now claimable for periods from July 2020 - December 2024 (2024) : Input VAT of £656,984 was payable and output VAT of £1,621,638 was claimable for periods from July 2020 - December 2023.

13. Tangible assets

	Office Equipment	Computer Equipment	Leasehold Improvements	Total
Cost	£	£	£	£
At 1 January 2025	112,779	183,959	249,760	546,498
Additions	42,077	3,333	-	45,410
Disposals	-	-	-	-
At 31 December 2025	154,856	187,292	249,760	591,908
Accumulated Depreciation				
At 1 January 2025	3,537	154,477	140,159	298,173
Charge for the year	41,028	14,026	30,132	85,186
Release on disposal	-	-	-	-
At 31 December 2025	44,565	168,503	170,291	383,359
Net book value				
At 31 December 2025	110,291	18,789	79,469	208,549
At 31 December 2024	109,242	29,482	109,601	248,325

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

14. Investments

Shares in Group Undertakings	£
Costs and net book value	
At 31 December 2025 and 31 December 2024	1

The company's wholly owned subsidiary, Delete Blood Cancer UK Marketing Limited, registered at Ashburnham House, Castle Row, Horticultural Place, London W4 4JQ is a dormant company. Its net liability position at 31 December 2025. £10,245 (2024: £10,245) is represented by amounts due to parent company and is fully provided for in the accounts of the parent company.

15. Inventory

Inventory costs were as follows:

	2025	2024
	£	£
Materials stock	104,265	50,999
Work in progress costs	10,432	9,689
Total	114,697	60,688

Inventories are valued at lower of cost and net realisable value. Work in progress costs are reimbursable costs incurred for active stem cell collections awaiting to be billed.

16. Debtors

	2025	2024
	£	£
Due within one year		
Trade debtors	1,729,935	1,949,139
Amounts owed by group undertakings	10,245	10,245
Amounts owed by related charity	815,196	217,495
Other debtors	880,398	495,757
Prepayments and accrued income	119,756	252,175
Total	3,555,530	2,924,811

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

17. Creditors: Amounts falling due within one year

	2025	2024
	£	£
Trade creditors	541,616	431,061
Amounts owed to related charity	8,337	6,929
Other creditors	82,451	109,038
Deferred revenue - UK Gala	-	223,519
Other taxation and social security	102,113	80,899
Accruals	659,650	610,957
Total	1,394,167	1,462,403

Other creditors include £Nil (2024: £223,519) deposits received for the fundraising event as no UK Gala is scheduled to be held in 2026

18. Financial instruments

	2025	2024
	£	£
Financial assets		
Financial assets that are debt instruments measured at amortised cost	3,435,774	2,672,636
Financial liabilities		
Financial liabilities measured at amortised cost	(549,953)	(437,990)
Total	2,885,821	2,234,646

Financial assets measured at amortised cost include trade debtors, amounts owed by group companies, other debtors and amounts owed by related charity.

Financial liabilities include trade creditors and amounts owed to a related charity.

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

19. Summary of funds

	2025	2024
	£	£
At 1 January	2,659,153	2,687,912
Income for year	14,891,498	12,896,254
Resource expended	(15,414,454)	(13,889,667)
Net income relating to prior year VAT treatment change	795,388	964,654
At 31 December	2,931,585	2,659,153

20. Analysis of net assets between funds

Analysis of net assets between funds - current year:

	Unrestricted funds 2025	Total funds 2025
	£	£
Tangible fixed assets	208,549	208,549
Fixed asset investments	1	1
Current assets	4,117,202	4,117,202
Creditors due within one year	(1,394,167)	(1,394,167)
Total	2,931,585	2,931,585

Analysis of net assets between funds - prior year:

	Unrestricted funds 2024	Total funds 2024
	£	£
Tangible fixed assets	248,325	248,325
Fixed asset investments	1	1
Current assets	3,873,230	3,873,230
Creditors due within one year	(1,462,403)	(1,462,403)
Total	2,659,153	2,659,153

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

21. Reconciliation of net movement in funds to net cash flow
from operating activities

	2025	2024
	£	£
Net income for the year (as per Statement of Financial activities)	272,432	(28,759)
Adjustment for		
Depreciation charges	85,186	52,698
Loss on disposal	-	488
(Increase) in debtors	(630,719)	(866,790)
Increase / (Decrease) in creditors	(68,236)	(121,329)
Decrease in inventory	(54,009)	198,008
Total	(395,346)	(765,684)

22. Analysis of cash and cash equivalents

	2025	2024
	£	£
Cash at bank and in hand	446,975	887,731
Total	446,975	887,731

23. Operating lease commitments

At 31 December 2024 the total of the charity's future minimum lease payments under non-cancellable operating leases was:

	2025	2024
	£	£
Within 1 year	266,951	266,951
Between 2 and 5 years	473,199	740,150
Over 5 years	-	-
Total	740,150	1,007,101

Lease payments recognised as an expense amounted to £278,574 (2024: £270,705).

The company entered into a new 10 year lease ending 30 September 2033 with a break clause at end of year 5 for its current office premises at annual rent of £266,220

DKMS Foundation: Notes to the financial statements
for the year ended 31 December 2025

24. Related party transactions

The company has taken advantage of the exemption contained in FRS 102 section 33 "Related Party Disclosures" from disclosing transactions with entities which are a wholly owned part of the group.

Transactions with other related parties are as follows:

Name (relationship)	Transaction	Amount		Amount due from / (to) related party	
		2025	2024	2025	2024
		£	£	£	£
DKMS Donor Centre gGmbH (Common Trustees)	Donated services	8,671	6,250	(99)	(395)
DKMS Group gGmbH (Common Trustees)	Donated services	1,099,216	1,062,112	-	-
DKMS Group gGmbH (Common Trustees)	ATT	228,640	230,000	-	-
DKMS Group gGmbH (Common Trustees)	Intercompany recharges	564,710	477,048	-	-
DKMS Group gGmbH (Common Trustees)	Interco funding	4,029,338	1,792,036	815,269	186,351
DKMS Registry Gemeinnutzige GmbH	Intercompany service provision	88,694	102,058	(6,970)	(5,665)
DKMS USA (Common Trustees)	Intercompany service provision and recharges	15,969	29,747	(669)	(839)
DKMS USA (Common Trustees)	International money donation	-	50,519	-	-
DKMS ASIA (India)	Intercompany support services	2,902,117	1,650,873	-	-
DKMS BMST (India)	Intercompany support services	429,516	1,011,916	-	-
DKMS Foundation (India)	Intercompany support services	691,865	-	-	-
DKMS Foundation NPC (South Africa)	Intercompany service provision	27,737	35,879	-	14,696
Fundacja DKMS (Poland)	Intercompany Recharges	-	1,695	-	1,695

Amounts owed to related parties are unsecured, interest free and due for repayment within one year.

DKMS Group gGmbH is the Controlling company and exercises full control over the charitable company through its common Trustees who are also directors of the company. The controlling company recharges the charitable company actual or appropriately apportioned costs it incurs in providing support to the latter.

The controlling company DKMS Group gGmbH entered into a contract with DKMS Life Science Lab whereby DKMS Foundation receives typing services for no consideration from 01 January 2021.

DKMS Life Science Lab is one of the leading HLA laboratories and provides this service for all DKMS entities.

25. Post balance sheet events

No post balance sheet events.

26. Controlling party

The trustees are the immediate controlling party and DKMS Group gGmbH is the ultimate controlling party. The principal address of the ultimate parent is Kressbach 1, 72072 Tübingen, Germany.

Copies of the group financial statements are available at www.dkms.de.





Ways you can support us



Organise a donor registration event

Organise an event to encourage your friends, family or colleagues to register as potential stem cell donors.



Sponsored activities

From local 10k runs and marathons to multi-day cycle trips, challenge yourself and get fit!



Payroll giving

Donate to DKMS through your company's Payroll Giving Scheme if employees are paid through PAYE.



The 2K Club

Join our club of corporate supporters whose contribution goes towards helping the more than 2,000 people in the UK searching for a matching stem cell donor each year.



Create a bespoke partnership

DKMS can provide your company with networking and marketing opportunities aligned with our purposes and shared values.



Daredevil challenges

If you fancy standing on top of a plane, jumping out of one, or filling your run with obstacles, we have something for everyone.



Fundraising events

Whether holding a bake sale, organising a music night or giving up a vice, every penny you raise helps in the fight against blood cancer.



Giving in memory

Many people choose to remember a loved one by fundraising for DKMS. We'll help you through the process to make sure their memory lives on through our work.





A Huge Thank You

We would like to say a huge thanks to all Charitable Trust funders and Foundations who gave us their generous and ongoing support especially:

C.A. Charitable Trust

Belron International Limited

PF Charitable Trust

Bridge Point Charitable Trust

Doris Field Charitable Trust

Trustees

Dr. E Neujahr
B J Abel
Bernd Weinel
Dr. A H Schmidt (resigned 22nd January 2025)
S Schumacher

Principal staff

Hasnein Alidina (retired 31st January 2026),
Country Manager, Finance and Operations

Peter McCleave, Country Manager,
Communications and Engagement

Registered company number

08151279

Charity registered number

1150056 (England & Wales)
SC046917 (Scotland)

Registered office

Ashburnham House, Castle Row,
Horticultural Place
London W4 4JQ

Company secretary

B J Abel

Independent auditors

Forvis Mazars LLP
6 Sutton Plaza
Sutton Court Road
Sutton
Surrey
SM1 4FS

Bankers

Barclays Bank plc
74 Shepherds Bush Green
Shepherds Bush
London W12 8QD

Commerzbank AG
30 Gresham Street
London EC2V 7PG



134k

Transplants for people in need



13.2m

Potential donors registered



27

Lifesaving stem cell donations each day*

*Global DKMS statistics as of 31 December 2025



dkms.org.uk

DKMS is the trading name of DKMS Foundation, a company limited by guarantee registered in England and Wales (08151279) and a charity registered in England and Wales (1150056) and Scotland (SC046917).